Progress in Antiretroviral Research
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: closed (30 June 2025) | Viewed by 1907
Special Issue Editor
Special Issue Information
Dear Colleagues,
Recommended antiretroviral therapy, consisting of two nucleoside analogues and a third agent (integrase inhibitor, non-nucleoside reverse transcriptase inhibitor, or boosted protease inhibitor), must be taken everyday (7 days/week) for life, with a risk of reduced adherence and long-term toxicity. In recent years, different strategies have been studied to reduce the exposure of people living with HIV (PLWH) to antiretroviral drugs and to improve their adherence and quality of life, while maintaining safety and virological suppression. Long-acting agents used to treat HIV infection will be the future, and cabotegravir and rilpivirine are the first to be used. Meanwhile, “intermittent” or “short-cycle” therapy (SCT) has received considerable attention. This strategy allows PLWH to take their antiretroviral drugs at standard doses and in combination for a limited number of consecutive days (generally 4 or 5 days) per week and interrupt the treatment during the weekend (Friday to Sunday or Saturday to Sunday).
Dr. Massimiliano Lanzafame
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antiretroviral therapy
- short cycle therapy
- HIV infection
- long-acting agents
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
